Huina Zhang1, Ioana Moisini1, Rana M Ajabnoor2, Bradley M Turner1, David G Hicks3. 1. Department of Pathology, University of Rochester Medical Center, Rochester, NY, 14642, USA. 2. Department of Pathology, Faculty of medicine, King Abdulaziz University, Jeddah, 21589, Kingdom of Saudi Arabia. 3. Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 626, Rochester, NY, 14642, USA. David_Hicks@URMC.Rochester.edu.
Abstract
PURPOSE OF REVIEW: The human epidermal growth factor receptor 2 (HER2) is an important prognostic and predictive biomarker in the breast cancer. The American Society of Clinical Oncology/College of American Pathology (ASCO/CAP) has published HER2 testing guidelines in breast cancer. We herein reviewed the HER2 testing guidelines in breast cancer with a focus on the application of the current guidelines. RECENT FINDINGS: The continual investigation of HER2 testing in breast cancer has resulted in updates in the HER2 testing guidelines. The current guidelines focus on the uncommon clinical scenarios and emphasize the coordination between immunohistochemistry and in situ hybridization results, in an effort to improve clarity and accuracy. The ASCO/CAP guidelines provide valuable recommendations to ensure the accurate evaluation of HER2 status in breast cancer patients through standardization. Additional studies, particularly those with long-term outcome data are still needed to validate the guideline recommendations, especially the uncommon cases.
PURPOSE OF REVIEW: The humanepidermal growth factor receptor 2 (HER2) is an important prognostic and predictive biomarker in the breast cancer. The American Society of Clinical Oncology/College of American Pathology (ASCO/CAP) has published HER2 testing guidelines in breast cancer. We herein reviewed the HER2 testing guidelines in breast cancer with a focus on the application of the current guidelines. RECENT FINDINGS: The continual investigation of HER2 testing in breast cancer has resulted in updates in the HER2 testing guidelines. The current guidelines focus on the uncommon clinical scenarios and emphasize the coordination between immunohistochemistry and in situ hybridization results, in an effort to improve clarity and accuracy. The ASCO/CAP guidelines provide valuable recommendations to ensure the accurate evaluation of HER2 status in breast cancerpatients through standardization. Additional studies, particularly those with long-term outcome data are still needed to validate the guideline recommendations, especially the uncommon cases.
Entities:
Keywords:
ASCO/CAP guideline; Breast cancer; HER2; Testing
Authors: Edith A Perez; Vera J Suman; Nancy E Davidson; Silvana Martino; Peter A Kaufman; Wilma L Lingle; Patrick J Flynn; James N Ingle; Daniel Visscher; Robert B Jenkins Journal: J Clin Oncol Date: 2006-07-01 Impact factor: 44.544
Authors: John D Hainsworth; Funda Meric-Bernstam; Charles Swanton; Herbert Hurwitz; David R Spigel; Christopher Sweeney; Howard Burris; Ron Bose; Bongin Yoo; Alisha Stein; Mary Beattie; Razelle Kurzrock Journal: J Clin Oncol Date: 2018-01-10 Impact factor: 44.544
Authors: Somaye Y Zare; Leo Lin; Abrar G Alghamdi; Svenja Daehne; Andres A Roma; Farnaz Hasteh; Marie Dell'Aquila; Oluwole Fadare Journal: Hum Pathol Date: 2018-08-16 Impact factor: 3.466
Authors: P L Fitzgibbons; D L Page; D Weaver; A D Thor; D C Allred; G M Clark; S G Ruby; F O'Malley; J F Simpson; J L Connolly; D F Hayes; S B Edge; A Lichter; S J Schnitt Journal: Arch Pathol Lab Med Date: 2000-07 Impact factor: 5.534
Authors: Angela N Bartley; Mary Kay Washington; Carol Colasacco; Christina B Ventura; Nofisat Ismaila; Al B Benson; Alfredo Carrato; Margaret L Gulley; Dhanpat Jain; Sanjay Kakar; Helen J Mackay; Catherine Streutker; Laura Tang; Megan Troxell; Jaffer A Ajani Journal: J Clin Oncol Date: 2016-11-14 Impact factor: 44.544
Authors: D C Allred; G M Clark; A K Tandon; R Molina; D C Tormey; C K Osborne; K W Gilchrist; E G Mansour; M Abeloff; L Eudey Journal: J Clin Oncol Date: 1992-04 Impact factor: 44.544
Authors: M Hofmann; O Stoss; D Shi; R Büttner; M van de Vijver; W Kim; A Ochiai; J Rüschoff; T Henkel Journal: Histopathology Date: 2008-04-18 Impact factor: 5.087
Authors: David B Page; Hannah Wen; Edi Brogi; Dana Dure; Dara Ross; Kateri J Spinelli; Sujata Patil; Larry Norton; Clifford Hudis; Heather L McArthur Journal: Breast Cancer Res Treat Date: 2017-10-06 Impact factor: 4.872
Authors: Caterina Marchiò; Maryou B Lambros; Patrizia Gugliotta; Ludovica Verdun Di Cantogno; Cristina Botta; Barbara Pasini; David S P Tan; Alan Mackay; Kerry Fenwick; Narinder Tamber; Gianni Bussolati; Alan Ashworth; Jorge S Reis-Filho; Anna Sapino Journal: J Pathol Date: 2009-09 Impact factor: 7.996
Authors: Emad A Rakha; Islam M Miligy; Cecily M Quinn; Elena Provenzano; Abeer M Shaaban; Caterina Marchiò; Michael S Toss; Grace Gallagy; Ciara Murray; Janice Walshe; Ayaka Katayama; Karim Eldib; Nahla Badr; Bruce Tanchel; Rebecca Millican-Slater; Colin Purdie; Dave Purnell; Sarah E Pinder; Ian O Ellis; Andrew H S Lee Journal: Br J Cancer Date: 2021-03-24 Impact factor: 7.640
Authors: Michalina Janiszewska; Shayna Stein; Otto Metzger Filho; Jennifer Eng; Natalie L Kingston; Nicholas W Harper; Inga H Rye; Maša Alečković; Anne Trinh; Katherine C Murphy; Elisabetta Marangoni; Simona Cristea; Benjamin Oakes; Eric P Winer; Ian E Krop; Hege G Russnes; Paul T Spellman; Elmar Bucher; Zhi Hu; Koei Chin; Joe W Gray; Franziska Michor; Kornelia Polyak Journal: JCI Insight Date: 2021-06-08